Ceftriaxone induced hemolysis complicated by acute renal failure by Kapur, Gaurav et al.
2. Masson E, Synold TW, Relling MV, et al. Allopurinol inhibits de
novo purine synthesis in lymphoblasts of children with acute
lymphoblastic leukemia. Leukemia 1996;10:56–60.
3. Nelson SC, Bruggers CS, Kurtzberg J, et al. Management of
leukemic hyperleukocytosis with hydration, urinary alkalinization,
and allopurinol. Are cranial irradiation and invasive cytoreduction
necessary? Am J Pediatr Hematol Oncol 1993;15:351–355.
4. Basade M, Dhar AK, Kulkarni SS, et al. Rapid cytoreduction in
childhood leukemic hyperleukocytosis by conservative therapy.
Med Pediatr Oncol 1995;25:204–207.
5. Schrappe M, Reiter A, ZimmermannM, et al. Long-term results of
four consecutive trials in childhood ALL performed by the ALL-
BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster.
Leukemia 2000;14:2205–2222.
6. Schwartz CL, Thompson EB, Gelber RD, et al. Improved response
with higher corticosteroid dose in children with acute lympho-
blastic leukemia. J Clin Oncol 2001;19:1040–1046.
7. Fiselier T, Monnens L, Moerman E, et al. Influence of the stress of
venepuncture on basal levels of plasma renin activity in infants and
children. Int J Pediatr Nephrol 1983;4:181–185.
8. Bhisitkul DM, Morrow AL, Vinik AI, et al. Prevalence of stress
hyperglycemia among patients attending a pediatric emergency
department. J Pediatr 1994;124:547–551.
9. RoseRM,HurstMW.Plasma cortisol and growth hormone responses
to intravenous characterization. J Human Stress 1975;1:22–36.
10. Mason JW, Sachar EJ, Fishman JR, et al. Corticosteroid responses
to hospital admission. Arch Gen Psychiatry 1965;13:1–8.
11. MeeranK,HattersleyA,MouldG, et al. Venepuncture causes rapid
rise in plasma ACTH. Br J Clin Pract 1993;47:246–247.
12. Kamada AK, Wiener MB, LaVallee NM, et al. A pharmacokinetic
comparison of two oral liquid glucocorticoid formulations.
Pharmacotherapy 1997;17:353–356.
13. Duzova A, CetinM, Gumruk F, et al. Acute tumour lysis syndrome
following a single-dose corticosteroid in children with acute
lymphoblastic leukaemia. Eur J Haematol 2001;66:404–407.
14. Rajagopal S, Lipton JH, Messner HA. Corticosteroid induced
tumor lysis syndrome in acute lymphoblastic leukemia. Am J
Hematol 1992;41:66–67.
15. Tiley C, Grimwade D, Findlay M, et al. Tumour lysis following
hydrocortisone prior to a blood product transfusion in T-cell acute
lymphoblastic leukaemia. Leuk Lymphoma 1992;8:143–146.
16. Luna-Fineman S, Healy MV, Parker BR. Corticosteroid pretreat-
ment for potential contrast reactions in children with lymphor-
eticular cancer: A word of caution. AJR Am J Roentgenol 1990;
155:357–358.
17. Smith T. Tumor lysis syndrome after steroid therapy for
anaphylaxis. South Med J 1988;81:415–416.
18. Loosveld OJ, Schouten HC, Gaillard CA, et al. Acute tumour lysis
syndrome in a patient with acute lymphoblastic leukemia after a
single dose of prednisone. Br J Haematol 1991;77:122–123.
Ceftriaxone Induced Hemolysis Complicated by
Acute Renal Failure
Gaurav Kapur, MD,1* Rudolph P. Valentini, MD,1 Tej K. Mattoo, MRCP, MD,1
Indira Warrier, MD,2 and Abubakr A. Imam, MD1
INTRODUCTION
Drug induced hemolytic anemia (HA) is an immune mediated
process in which antibodies react against the red blood cells (RBC).
Risk of clinical blood dyscrasias is increased fivefold among
patients receiving antibiotics and is highest with cephalosporins [1].
Since the first report of severe intravascular immune hemolytic
anemia (IHA) with cefotaxime [2], second and third generation
cephalosporins have been reported as the most common cause of
drug-induced HA [3]. More than 50% of all reported cases of IHA
associated with third-generation cephalosporins are related to
ceftriaxone [4]. A fatal outcome is more common in ceftriaxone-
induced HA than in IHA associated with other drugs [4].
Ceftriaxone induced HA in children is more common in patients
with underlying hematological and immune dysfunction. We
present a pediatric case, who survived acute renal failure (ARF)
secondary to ceftriaxone-induced HA.
CASE REPORT
A 10-year-old Caucasian male with a past medical history
significant for craniosynostosis was evaluated for scalp abscess on
right temporal area which was incised and drained. Patient had
received one dose of intravenous (I/V) ceftriaxone and two doses of
Over the last decade, second and third generation cephalospor-
ins have been the most common drugs causing hemolytic anemia
(HA). Of these cases, 20% have been attributed to ceftriaxone. The
clinical presentation of ceftriaxone-induced HA is usually abrupt
with sudden onset of pallor, tachypnea, cardio-respiratory arrest and
shock. Acute renal failure (ARF) has been reported in 41% of such
cases with a high fatality rate. We report a pediatric patient with ARF
complicating ceftriaxone-induced HA who survived. Ceftriaxone is a
commonly used drug, and early recognition of HA and institution of
supportive care, including dialysis is likely to improve the outcome.
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clindamycin and was sent home on cephalexin 250 mg orally four
times a day. The patient developed superficial infection of the skin
and underlying temporal shield. He was readmitted and started on
I/V clindamycin (250 mg) every 6 hr. The patient had surgical
removal of the temporal shield and switched to I/V ceftriaxone
(1 g twice a day). After receiving the third dose of ceftriaxone, he
developed a maculopapular rash starting at the upper torso and
spreading to involve the face and abdomen with itching all over the
body. Patient also developed mild facial puffiness. There was no
associated wheezing, shortness of breath, or arthritis. Subsequently
the patient was noticed to have deterioration of his mental status
associated with decreasing urine output. He became anuric 1 day
later. His serum creatinine increased from 1.1mg/dl on admission to
5.4 mg/dl over a period of 4 days. His hemoglobin dropped from
12.4mg/dl to 8.7mg/dl during the sameperiod. Therewas no history
of excessive blood loss at surgery. The patient was transferred to
Children’s Hospital of Michigan for management of his ARF.
On admission the patient was drowsy, but responsive, with a
pulse of 111/min, BP 122/80 and respiratory rate 15/min. Apart
from mild facial puffiness, rest of the physical examination was
within normal limits. His investigations revealed: Blood urea
nitrogen (BUN) 34 mg/dl, creatinine 6.9 mg/dl, sodium 138 meq/
L, potassium 4.6 meq/L, phosphorus 5.6 mg/dl, Lactate dehydro-
genase (LDH) 3867 U/L, serum albumin 2.3 mg/dl. Rest of the
blood chemistry included normal complements, liver function
tests, creatinine kinase and antistreptolysinO (ASO) titer. His
hematology workup revealed hemoglobin 8.4 g/dl, platelets
112 103/mm3, reticulocyte count 4.5%, D-dimer 400–800 ng/
ml (normal<200 ng/ml), fibrinogen 1056mg/dl (158–416mg/dl),
activated partial thromboplastin time (APTT) 33.1 sec and
prothrombin time (PT) 11.1 sec. Broad spectrum andmonospecific
Coombs (C3d, IgG) tests were negative. The patient’s peripheral
smear showed normocytic normochromic red cells with no
evidence of schistocytes or eosinophilia. His immunological
workup included negative serology for antinuclear antibody
(ANA),HIVand normal immunoglobulin levels. His urine analysis
revealed specific gravity 1015, pH 7.0, protein 100 mg/dl,
2þ leukocyte esterase, >100 RBC/HPF, >100 WBC/HPF, and
no casts or myoglobinuria. A renal ultrasound with Doppler
revealed large echogenic kidneys with normal resistive indices.
The patient underwent a renal biopsy for the evaluation of the
cause of his renal failure and peritoneal dialysis was initiated. The
renal biopsy showed acute tubular necrosis with hemoglobin casts
within the tubular lumen (Fig. 1). There was no evidence of
interstitial nephritis on the renal biopsy. He received peritoneal
dialysis for 2½ weeks. Subsequently, his renal function and urine
output gradually recovered. The patient’s serum creatinine
normalized at 0.7 after 6 weeks of onset of symptoms.
DISCUSSION
Adverse drug reactions are a major clinical problem account-
ing for 2–6% of all hospital admissions [5]. Of the total 17
reported cases of ceftriaxone-induced hemolysis, 61% have been
reported in children [4,6–20]. Ceftriaxone-induced hemolysis
has a 63% fatality rate in children and 40% in adults. In 41% of
these patients, the clinical course has been complicated by ARF
with invariably poor outcome (Table I). The review of these
[4,10,13] revealed that 10 out of 11 cases had an underlying
immune or hematological dysfunction and were frequently
associated with a history of recurrent infections. In these cases,
re-exposure or continued treatment with ceftriaxone might be
critical determinants for development of drug dependent anti-
bodies. Normal RBC morphology on peripheral smear, negative
Coombs test, neonatal screening (history) and immunological
workup excluded any significant intrinsic RBC or immunological
disorder in our patient. Although, this workup for underlying
intrinsic RBC or immune disorder was minimal, there was no
obvious disorder detected.
The second and third generations of cephalosporins have been
reported as the most common cause of drug-induced HA [3]. The
mechanisms that have been proposed to explain drug induced HA
include: (1) drug adsorption; (2) immune complex; (3) membrane
modification and (4) true antibody formation [21]. A unifying
hypothesis proposes that drug/drug metabolites interact with the
RBC membrane causing composite immunogenic epitopes that
are recognized as foreign by the immune system [22,23]. The
antibodies produced may react with the drug (in penicillin induced
HA), the drug-RBC complex (in ceftriaxone induced HA) or the
membrane alone (in methyldopa induced HA). Recently it has
been reported, that except for ceftriaxone, the second and third
generation cephalosporins appear to induce all three-antibody
populations [3]. Ceftriaxone appears to induce only antibodies that
elicit immune complex type of in vitro reaction and is associated
with a high fatality [3]. The hemolysis due to complement activa-
tion by these antibodies is abrupt and is usually intravascular. The
resulting hemoglobinuria is nephrotoxic particularly when intra-
tubular obstruction facilitates proximal tubular heme uptake [24].
The negative DAT test in our patient could be due to the sudden
massive hemolysis occurring with ceftriaxone and therefore the
lack of sensitized RBC with C3d and IgG at the time of testing
when the patient presented to us. Also the LDH showed a
decreasing trend subsequently which showed that the hemolysis
was sudden andmassive and did not continue once ceftriaxonewas
stopped. The diagnosis of ceftriaxone-induced HA in our patient
was based on laboratory evidence of hemolysis and renal biopsy
showing hemoglobin-laden tubules with acute tubular necrosis.
The most effective treatment of patients who develop drug
dependent IHA is immediate discontinuation of the drug [22],
Pediatr Blood Cancer DOI 10.1002/pbc
Fig. 1. Renal biopsy showing hemoglobin laden tubules and normal
glomeruli. [Color figure can be viewed in the online issue, which is
available at www.interscience.wiley.com.]
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whichwas the case in our patient. Of the reported cases, almost one
third of the patients continued to receive the drug after an initial
allergic reaction to ceftriaxone as they were diagnosed retro-
spectively.
In conclusion, ceftriaxone can cause fatal hemolysis and should
be used with caution especially in patients who are immunocom-
promised or have an underlying hematological condition. ARFmay
be the presenting manifestation of ceftriaxone-induced IHA and the
prognosis may be favorable for recovery with early diagnosis and
initiation of supportive therapy including dialysis.
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Large Granular Lymphocyte Leukemia (LGL) in a Child With
Hyper IgM Syndrome and Autoimmune Hemolytic Anemia
Brenda J. Kitchen, MD* and Laurence A. Boxer, MD
INTRODUCTION
Large granular lymphocyte leukemia (LGL) is a rare, indolent
form of non-Hodgkin’s lymphoma. This clonal lymphoproliferative
disease arises most frequently fromT-cells and less commonly from
natural killer (NK) cells [1]. The median age at presentation is 60
years old with less than 10% of patients younger than 40 years of
We describe a female with a history of autosomal recessive
hyper-IgM (HIGM) syndrome along with a history of autoimmune
hemolytic anemia and intermittent lymphadenopathy. She subse-
quently developed neutropenia, lymphocyostosis and mild throm-
bocytopenia. Flow cytometry of the peripheral blood revealed the
presence of a marked predominance of cytotoxic T lymphocytes,
shown to be clonal, with concomitant natural killer (NK) antigen
expression. She responded to weekly methotrexate therapy. Pediatr
Blood Cancer 2008;50:142–145.  2006 Wiley-Liss, Inc.
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